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Genetic determinants of the epigenome in
development and cancer
Bird Adrian
Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK
Summary
Although we have detailed maps of epigenetic marks on
DNA and chromatin for many cell types and disease
states, the origin and significance of these patterns is in-
completely understood. Deregulation of the epigenome is
a frequent accompaniment to cancer, and it is therefore
important that we learn how it contributes to tumour forma-
tion. Here it is proposed that the roles of DNA sequence
signals as determinants of the epigenome have been un-
derappreciated. Taking as a paradigm the part played by
the dinucleotide CpG in regulating gene expression via
its effects on the epigenome, it is suggested that factors
recognising other short, frequent sequence motifs also re-
cruit chromatin modifying enzymes in response to DNA
sequence. A screen for factors of this kind promises to aid
our understanding of the mechanisms by which gene ac-
tivity is globally regulated.
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Introduction
Proteins that recognise specific DNA base sequences are
uniquely able to target biological activity to a specific
“address” in genomic DNA. It follows that development
and maintenance of multiple cell types will be largely
achieved by varying the availability of sequence-specific
factors of this kind, which in turn enable specific genetic
programmes by activating or repressing genes. Attractive
though this hypothesis may be, there is evidence that the
“transcription factors-only” scenario is oversimplified.
Specifically, epigenetic marking, laid down during the de-
velopmental history of the cell, may be required to “con-
dition” the response of the genome to transcription factors.
In support of a role for epigenetics, reprogramming of cell
fate exclusively by transcription factors is an inefficient
process [1], suggesting that chromatin conditioning may
help to buffer the cell against phenotypic change. More-
over, an increasing number of disease states involve mis-
regulation of readers, writers or erasers of epigenetic infor-
mation, emphasising their key role as modulators of gene
activity. This is particularly striking in the case of cancer,
where global redistribution of DNA methylation is well
documented, but not fully understood [2]. These findings
highlight our need to understand the forces that define the
epigenome. It is normally considered that developmental
history, disease or the influence of the environment are pri-
mary epigenome determinants (fig. 1) and consequently
that disease states may also be triggered in this way. This
article considers the alternative possibility that the epige-
netic patterning is determined to a significant extent by the
underlying genomic DNA sequence.
Patterns of DNA methylation
Methylation of the vertebrate genome is largely biphasic.
The vast majority of DNA, including gene bodies, inter-
genic DNA transposable elements and other repeats, is
highly methylated at CpGs, but a small fraction (about 2%)
comprises CpG islands (CGIs), which are methylation-free
patches surrounding promoters (fig. 2). A long-standing
paradox is that CGIs are usually free of DNA methyla-
tion, despite containing an abnormally high concentration
of the methylate-able sequence CpG [3]. Earlier work from
this laboratory and others showed that in mice, sites for
the transcription factor Sp1 are required to prevent DNA
methylation [4, 5]. More recently the Schübeler laborato-
ry has documented the negative influence of transcription
Figure 1: High level influences on the epigenome. The
epigenome encompasses all of chemical information that is added
to the genome in a cell, in particular via modification of histones or
DNA. The origin of these patterns of modification is incompletely
understood. There is particular interest in the role of the environ-
ment, although the evidence supporting this route is sometimes
controversial. This article considers that DNA sequence may be an
under-appreciated determinant of the epigenome.
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factor-binding sites on local methylation status [6, 7]. Al-
though reduced DNA methylation at promoters and en-
hancers is partly due to binding of transcription factors,
presumably via steric interference with DNA methyltrans-
ferase (Dnmt) access [7], this mechanism is unlikely to ex-
plain the CGI phenomenon where methylation is absent
at many CpG sites over hundreds of base pairs. An alter-
native explanation is that de novo Dnmts are excluded by
chromatin bearing the H3K4me3 mark [8]. Indeed CGIs
mark many promoters and frequently coincide with peaks
of H3K4me3 and this is therefore likely to contribute to
their immunity to DNA methylation. Promoter activity is
not required to exclude DNA methylation, however, as ar-
tificial CGI-like constructs that are transcriptionally inert
nevertheless remain DNA methylation-free [9]. This may
be due to the presence of CXXC domains in all H3K4
methyltransferases, which recognise and bind to the CpG
dinucleotide regardless of transcription and may recruit
these enzymes to CGIs. Further studies of artificial CGIs
have uncovered evidence that, in addition to CpG density,
base composition per se is important for CGI function, as
AT-rich DNA reproducibly succumbs to DNA methylation,
whereas GC-rich DNA is methylation resistant. These AT-
rich sequences can still recruit H3K4 methylation when
DNA methylation is excluded (that is, in Dnmt3a/b double
mutant cells), but this is evidently insufficient to render
them methylation-free in wild-type cells [9]. Exclusion of
DNA methylation is observed with a variety of unrelat-
ed synthetic sequences integrated into the embryonic stem
cell genome, even if the density of CpGs is kept at a
high level typical of CGIs. The transition between effec-
tive absence of methylation (<10%) and dense methyla-
tion (>85%) is quite sharp, with a midpoint near 55% GC.
These results provide unexpected evidence for an instruc-
tive effect of base composition per se on the epigenome.
Beyond CGIs, there are numerous examples where long
range alterations in DNA methylation levels correlate with
DNA base composition. This is particularly evident in can-
cer. For example, opposite shifts in the global distribution
of DNA methylation (i.e., AT-rich → GC-rich) are promi-
nent when normal human colon cells are compared with
colorectal cancer cells [2]. This also occurs in normal tis-
sues, as our recent analysis of DNA methylation land-
scapes in the human brain illustrates [10]. Analysis of
differentially methylated regions shows that in the cerebel-
lum, sequences losing DNA methylation relative to other
brain regions share a GC-rich base composition, whereas
regions gaining methylation are relatively GC-poor. These
results point to a global shift in DNA methylation, away
from GC-rich towards AT-rich sequences. Strikingly, cere-
bellum resembles ES cells, which also show absence of
CGI methylation, but high methylation of the AT-rich bulk
genome. Why the cerebellum should exhibit such a differ-
ent DNA methylome from other parts of the brain is entire-
ly unknown. Hypothetically, global redistribution of DNA
methylation may adjust and optimise gene expression lev-
els specific to this brain region, though experimental evi-
dence in support of this explanation is currently lacking.
DNA methylation and cancer – the role of mu-
tation
The role of DNA methylation in cancer has been the sub-
ject of intense study, but uncertainty remains regarding its
precise causal relevance. The cancer DNA methylome is
Figure 2: CpG and methyl-CpG have very different distributions across the genome. The dinucleotide CpG occurs in two chemical forms that
attract or repel different protein complexes (e.g., via CpG- or mCpG-binding proteins).
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evidently abnormal in several respects. In particular, CGI
promoters are often methylated and associated with silenc-
ing of the associated gene. Also, as mentioned above, hy-
pomethylation of large genomic domains is frequent. But
whether these effects are a primary or secondary effect of
disease and what upstream influences are responsible re-
main tantalisingly ill-defined. Potentially, de novo methy-
lation may cause a gene silencing event that initiates the
transition of a cell to a pre-cancerous state (e.g., by shut-
ting down a tumour suppressor gene). This would be the
most direct possible involvement of an epigenetic change
in tumorigenesis. Examples of “primary constitutional
epimutations” of this kind are rare, however, as most de
novo methylation events are accompanied by DNA se-
quence changes and these mutations are likely to be the
primary genetic trigger [11]. For example, the H19 gene is
normally mono-allelically expressed owing to imprinting,
but de novo methylation of the imprinting control region
on the maternal allele often accompanies paediatric Wilm’s
tumour. In 98 to 99% of cases, however, methylation is ac-
companied by a base sequence change, indicating that the
epigenetic change is almost always secondary. Similarly,
a variety of tumours can be initiated by de novo methy-
lation of the promoter of the MLH1 gene, whose product
is required for efficient mismatch repair, but only in 1 to
10% of cases is a primary constitutional epimutation im-
plicated. In the case of MLH2, another mismatch repair
gene, all examples of de novo CGI methylation so far as-
sociated with tumorigenesis appear to be downstream of
an altered DNA sequence. Thus examples where epige-
netic changes are clearly the root cause of cancer are few
and far between. This is not to argue that DNA methy-
lation plays no role in tumorigenesis, as there are many
examples where its secondary involvement appears to re-
inforce tumour growth or survival. Indeed, DNA methyl-
transferase inhibitors provide benefit in the clinic, indi-
cating a key supporting role for epigenetic changes that
may be further exploited therapeutically [12]. Moreover,
DNA methylomes have emerged as useful biomarkers for
tumour classification and progression [13].
CpG – a short, frequent motif that influences
the epigenome
How might base sequence influence the DNA methylome,
or, more broadly, the epigenome as a whole? Here I discuss
the possibility that local features of the genomic DNA se-
quence combine to exert a global influence on chromatin
modification and gene activity via DNA binding proteins
that recognise short, frequent sequence motifs [14]. The
best understood precedent for this assertion comes from
studies of the dinucleotide CpG. Despite the limited infor-
mation content of a two base-pair sequence, this motif has
several features that appear to adapt it as a genomic sig-
nalling module: (i) it can occur in several chemical states
as a result of methylation or hydroxymethylation (plus oth-
er oxidation states) of the cytosine moiety on position 5
of the cytosine ring; (ii) it is symmetrical, meaning it is
paired with the same sequence on the anti-parallel oppo-
site strand, a property that provides a mechanism for se-
mi-conservatively copying CpG methylation patterns onto
the daughter strand at DNA replication; (iii) its frequen-
cy is highly variable in the genome, ranging from dense
clusters at CGIs, to sparse underrepresentation in most of
the genome due to the mutagenic pressure associated with
DNA methylation; and (iv) last but not least, we know of
proteins that recognise different chemical forms of CpG
and appear to mediate effects on genome function [15, 16].
Maps of methylated and unmethylated CpGs often include
both forms together, usually as interspersed open and filled
circles. Given that the two motifs represent distinct DNA
binding signals, however, there is a case for displaying
them separately. The resulting maps emphasise their con-
trasting distributions (see fig. 2). The CpG map greatly
emphasises the clustering of unmethylated sites at CGIs,
whereas the mCpG map renders CGIs almost invisible. It is
evident that two such distinct landscapes will be interpret-
ed very differently by proteins with a specific affinity for
one motif. CpG readers include Cfp1, KDM2a, KDM2b
and Mll2, all of which possess a CXXC domain that binds
exclusively to unmethylated CpG in duplex DNA [17–22].
In contrast, MeCP2, MBD1, MBD2 and UHRF1, among
others, require methylated CpG to bind [23–26]. Most of
these motif readers influence chromatin modification states
by recruiting enzymatic complexes. Cfp1, for example, is
part of the Set1 complex that methylates lysine 4 of hi-
stone H3 (H3K4me3) and is found at CGIs. The coinci-
dence immediately suggests that Cfp1, by targeting CGIs,
may recruit the Set1 complex leading to deposition of
H3K4me3 (fig. 3), which is a signature histone mark at
CGIs [17, 27, 28]. In strong support of this scenario, ar-
tificial CGI-like sequences that are transcriptionally inert
acquire H3K4me3 when integrated into the genome [9,
17]. Studies of other proteins with CpG-binding CXXC
domains report similar recruitment of chromatin modify-
ing activities [19–21]. It appears that a major function of
CGIs is to attract proteins of this kind in order to facil-
itate regulation of gene expression. Methyl-CpG-binding
proteins, on the other hand, avoid unmethylated CGIs and
track CpG methylation across the genome. Unlike most
(but not all) CpG binding proteins, they generally associ-
ate with co-repressor complexes that inhibit gene expres-
sion and deacetylate histone tails (see fig. 3). For example,
MeCP2 recruits the NCoR/SMRT [29] and Sin3a corepres-
sors [30, 31], while Mbd2 is part of the NuRD co-repressor
complex [32].
Interestingly, the high frequency of CpGs within CGIs
does not appear to be the result of evolutionary selection
on individual CpG sites [33]. It seems instead that a GC-
rich base composition and lack of DNA methylation in
these regions over millions of years has been sufficient to
create by default a CpG-rich platform that is adaptive for
gene regulation. Thus although CpGs may not be directly
selected, there is compelling evidence that they are key to
CGI function, as the ability to recruit both H3K4me3 and
the polycomb group proteins depends on CpG density [17,
18, 20, 21, 34–36]. It follows that regions of GC-rich DNA
with correspondingly high densities of CpG exert an effect
on chromatin modification (including DNA methylation)
via CpG binding proteins. This aspect of the epigenome is
therefore directly influenced by DNA sequence context.
With the exception of CpG binders, little attention has been
paid to factors recognising other low complexity sequence
motifs. The following question arises: do short sequence
motifs other than CpG behave as genomic signalling mod-
ules and, if so, how are they read and what are their bi-
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ological effects? A pre-requisite for addressing this ques-
tion is the existence of candidate DNA binding proteins
that recognise sequence motifs that are sufficiently short or
redundant. For example, diverse proteins that contain AT-
hooks require only permutations of four As and Ts to bind
[37]. To capture these and other such proteins, it is possi-
ble to screen nuclear protein extracts from embryonic stem
cells for proteins that are reproducibly captured by AT-rich
DNA sequences. Our preliminary evidence indicates that
such a screen can recover proteins that bind AT-rich motifs
and whose function is linked to differentiation and disease,
as well as unstudied proteins about which little is known.
The molecular mechanisms underlying the biological func-
tions of these proteins are the focus of on-going research.
Is DNA base composition a signal that pro-
grammes the epigenome?
Apart from de novo methylation of DNA, there are several
features of chromosome organisation that correlate with
zones of differing base composition. Bernardi first recog-
nised that the genome is a mosaic of domains or “iso-
chores” with different sequence characteristics [38, 39].
Within an isochore, base composition is relatively homo-
geneous, ranging from GC-poor (~35%) to GC-rich
(~55%) and the boundaries between isochores are relative-
ly sharp. For several decades it has been recognised that
isochores map onto a variety of interesting chromosomal
features. These include regions of higher gene density and
early replicating regions (both GC-rich) [40] as well as
lamin-associated domains, regions of high LINE transpo-
son density and G bands (all AT-rich) [41, 42]. Is the asso-
ciation causal or consequential? One possibility is that base
composition is a passive by-product of features of chromo-
some structure and activity. Late replicating DNA, for ex-
ample, may be subject to biased mutation due to the com-
position of nucleotide pools at this stage of the cell cycle
[43]. An alternative view that has not so far been inves-
tigated is that DNA sequence composition drives aspects
of chromosome organisation. In this case base composition
would constitute a signal that could be read by DNA bind-
ing proteins. Since these global features of the epigenome
are subject to modulation between cell types, a key com-
ponent of this hypothesis is that sequence-specific factors
Figure 3: Non-methylated CpG islands recruit “active” histone marks, whereas methylated CpG islands lead to a repressive chromatin struc-
ture. CpGs are represented by circles that are either methylated (black) or non-methylated (white) on DNA that is wrapped around nucleo-
somes (pink cylinders). The CpG reader Cfp1 targets the SetD1 complex which methylates lysine 4 of histone H3. Other CpG readers also re-
cruit “active” chromatin modifiers. MBD proteins bind methylated CpG, either in methylated CpG islands or elsewhere in the genome and
recruit histone deacetylase complexes that inhibit transcription.
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Figure 4: Small differences in base composition cause large differ-
ences in AT motif frequency. Expected frequencies of A, AT etc.
are compared between two levels of AT-richness. For example,
compared with DNA of 40% AT, the sequence ATTA is 2.5 times
more frequent in 50% AT DNA and 5 times more frequent in 60%
AT DNA. The same approximate ratios would apply to other se-
quences of mixed A + T.
recognising short motifs will be expressed in a tissue-re-
stricted manner.
How might shared features of DNA base composition be
read as a signal even though the detailed underlying base
sequences are highly diverse? By analogy with CpG sig-
nalling in CGIs, we entertain the hypothesis that proteins
recognising short DNA sequence motifs carry out this
function. The rationale is that while the frequency of single
bases is linearly dependent on the base composition, the
frequency of runs of A/T tracts increases non-linearly as
AT-richness rises. For example, the single base A is 1.5
times more frequent in random DNA of 60% AT DNA
than in DNA of 40% AT, whereas the 5 base pair sequence
AAAAA (or TTAAT etc.) is >7 times more frequent (fig.
4). This means that the frequency of A/T runs of four to six
nucleotides is highly sensitive to base composition. There
are conceptual parallels with CpG, which is a known sig-
nalling sequence that occurs on average every 100 base
pairs in the bulk genome, but is locally an order of magni-
tude more frequent within CGIs. Candidate proteins recov-
ered in a preliminary screen for generalised AT-rich DNA
binding proteins are being tested in this laboratory to see if
they fulfil these requirements. Some of these are AT-hook
proteins, whereas others recognise AT-runs via unrelated
DNA binding domains. Many, but not all, of the proteins
are known and the biological effects of deficiency have
been assessed either from studies of human disease or by
gene disruption in mice. Molecular mechanisms underly-
ing these effects are in nearly all cases not understood. Our
current task is to select candidates whose role may be to
mediate the effects of base composition on chromosome
biology. In this way we hope to illuminate the role of ge-
netic information in determining the epigenome, and hence
in optimising gene expression.
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Figure 5: The logo of the Brupbacher foundation.
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